Catalogo dei prodotti della ricerca

TOMAO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.152
EU - Europa 2.077
AS - Asia 812
AF - Africa 57
SA - Sud America 36
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.142
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.064
IT - Italia 786
SE - Svezia 472
IN - India 414
CN - Cina 293
FI - Finlandia 221
UA - Ucraina 129
DE - Germania 122
CA - Canada 85
GB - Regno Unito 63
SG - Singapore 56
FR - Francia 47
BG - Bulgaria 45
IE - Irlanda 45
TG - Togo 44
RO - Romania 33
AT - Austria 29
BE - Belgio 26
AR - Argentina 23
NL - Olanda 13
CH - Svizzera 11
IR - Iran 11
BR - Brasile 9
HK - Hong Kong 8
AU - Australia 7
TR - Turchia 7
ZA - Sudafrica 7
ES - Italia 6
DK - Danimarca 5
GR - Grecia 5
MY - Malesia 5
PL - Polonia 5
CL - Cile 4
JP - Giappone 4
NO - Norvegia 4
EG - Egitto 3
KR - Corea 3
PH - Filippine 3
CZ - Repubblica Ceca 2
EE - Estonia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PT - Portogallo 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BZ - Belize 1
DO - Repubblica Dominicana 1
EU - Europa 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MX - Messico 1
RS - Serbia 1
SC - Seychelles 1
TN - Tunisia 1
Totale 10.142
Salva come PNG Salva come JPEG
Città #
Fairfield 1.232
Ashburn 705
Chandler 558
Woodbridge 524
Seattle 481
Wilmington 421
Cambridge 375
Houston 366
Ann Arbor 321
Rome 280
Princeton 234
Beijing 207
San Paolo di Civitate 181
Plano 175
Lawrence 128
Boston 115
Millbury 102
San Diego 90
Bremen 72
Helsinki 66
Dearborn 55
Andover 52
Norwalk 50
Sofia 45
Dublin 44
Lomé 44
Jacksonville 36
Toronto 34
New York 29
Vienna 28
Brussels 26
North York 26
Federal 23
Milan 20
Ottawa 20
Falls Church 17
Boardman 16
Fremont 16
Redwood City 15
San Mateo 15
Des Moines 13
Hefei 13
Phoenix 12
Grafing 10
Kunming 10
Paris 10
Southend 10
Bühl 9
Nanjing 9
London 8
Pune 8
Sacramento 8
Singapore 8
Washington 8
Buffalo 7
Guangzhou 7
Surrey 7
Hong Kong 6
Istanbul 6
Naples 6
Palermo 6
Adelaide 5
Florence 5
Indiana 5
Laurel 5
Mumbai 5
Turin 5
Bangalore 4
Changsha 4
Chicago 4
Hebei 4
Hyderabad 4
Muizenberg 4
Nanchang 4
Oslo 4
San Francisco 4
Vejle 4
Arezzo 3
Bologna 3
Cairo 3
Hamadacho 3
Henderson 3
Jinan 3
Leawood 3
Melegnano 3
Montecalvo Irpino 3
Montréal 3
Nanning 3
Pomezia 3
Prossedi 3
Provo 3
Seoul 3
São Paulo 3
Torino 3
Trumbull 3
Zanjan 3
Albuquerque 2
Bangkok 2
Belo Horizonte 2
Bengaluru 2
Totale 7.560
Salva come PNG Salva come JPEG
Nome #
Rucaparib. An emerging parp inhibitor for treatment of recurrent ovarian cancer 121
Fertility preservation in gynaecologic cancers 105
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 93
Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review 92
Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements 91
Bevacizumab in ovarian cancer: state of the art and unanswered questions 90
Complete remission of cerebral endometriosis with dienogest: a case report 89
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 88
Comparison of anogenital distance and correlation with vulvo-vaginal atrophy: a pilot study on premenopausal and postmenopausal women 87
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 86
Impact of hormone receptor status and Ki-67 expression on disease-free survival in patients affected by high-risk endometrial cancer 85
Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-Expressing Cells 83
Fertility preservation in ovarian tumours 83
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. 82
Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma. Younger and older patients should be equally treated. A prospective study and literature review 81
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients 81
Breast cancer risk after ovarian stimulation for In vitro fertilization 80
Unexpected Metastasis of High Grade Serous Ovarian Cancer to Breast: Case Report and Literature Review 80
The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D) 79
null 78
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment 78
G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)? 77
Pfizer-BioNtech COVID-19 vaccine in gynecologic oncology patients. A prospective cohort study 77
Current role and safety profile of aromatase inhibitors in early breast cancer 76
The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients 76
Cervical cancer: are there potential new targets? An update on preclinical and clinical results 75
Niraparib in ovarian cancer. results to date and clinical potential 75
A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report 75
Triple-negative breast cancer: investigating potential molecular therapeutic target 74
Benign schwannoma in supraclavicular region: a false-positive lymph node recurrence of breast cancer suspected by PET scan. 74
Adjuvant therapy for early uterine high-grade leiomyosarcoma 74
Endometriosis and pregnancy. a single institution experience 73
The EOLO (End-of-Life Ovarian Cancer) Study: Approach to ovarian cancer patients at the end of life 72
Triple negative breast cancer: new perspectives for targeted therapies 72
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 71
The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site 69
null 69
Immunologic treatments for precancerous lesions and uterine cervical cancer 69
Role of chemotherapy in the management of vulvar carcinoma 68
Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months 68
Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy 68
Angiogenesis and antiangiogenic agents in cervical cancer 67
Correlation between fertility drugs use and malignant melanoma incidence: the state of the art 67
Fertility-Sparing Options in Young Women with Cervical Cancer. 66
Paclitaxel and Alisertib in recurrent ovarian cancer 66
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial 66
A comparative analysis of serum and serum-free media for generation of clinical grade DCs 65
Intraperitoneal Chemotherapy: A Strategy for the Treatment of Refractory Ascites in Recurrent Endometrial Cancer Patients - Three Case Reports and Review of the Literature 65
Fertility drugs, reproductive strategies and ovarian cancer risk 63
Quality of life effects of ovarian suppression in the suppression of ovarian function trial 63
MODIFIED GLUTEAL FOLD ADVANCEMENT V-Y FLAP FOR VULVAR RECONSTRUCTION AFTER SURGERY FOR VULVAR MALIGNANCIES. 63
Accuracy of pelvic ultrasound in preoperative evaluation of uterine myomas: a prospective cohort study 63
THE IMPACT OF BONE METASTASIS SYMPTOMS OF ZOLEDRONIC ACID 62
Fertility drugs and breast cancer risk 62
Ovarian function, reproduction and strategies for fertility preservation after breast cancer 62
An Update of Laparoscopy in Cervical Cancer Staging: Is It a Useful Procedure? 61
Chemotherapy-induced nausea and vomiting in Italian cancer centers: Results of CINVDAY, a prospective, multicenter study 61
Hot flushes in women with breast cancer: State of the art and future perspectives 60
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies 60
Progesterone therapy in endometrial cancer 60
null 60
Non-pegylated liposomal doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients 60
Epistaxis in Weekly Paclitaxel Regimen: Is it Really Related to Schedule? 59
Imaging strategy in recurrent ovarian cancer: a practical review 59
The role of 2d/3d ultrasound to assess the response to neoadjuvant chemotherapy in locally advanced cervical cancer 58
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. 58
Current status of bevacizumab in advanced ovarian cancer 57
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. 57
Impaired uterine artery flow associated with the presence of ovarian endometrioma: preliminary results of a prospective study 57
OP29.03: Identification of parametria by 2D-3D ultrasound in patients with cervical cancer: new perspectives and future applications 56
Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100) 56
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: Basic knowledge and therapeutic possibilities for an innovative approach 56
null 56
null 55
Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. 55
Positron Emission Tomography (PET) radiotracers in oncology - utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC) 53
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer 53
null 53
Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts) 53
Late breast cancer recurrence to the uterine cervix with a review of the literature 53
Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies 53
Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy 53
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives 52
null 52
Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors 52
Breast cancer risk after exposure to fertility drugs 51
Anticancer treatment and fertility effects. Literature review 51
Special issues in fertility preservation for gynecologic malignancies 51
Metastatic infiltration of adenocarcinoma of the rectum in hard palate: Report of a case and a review of the literature 51
Evaluation of CA125 and HE4 diagnostic performance in hereditary and sporadic ovarian cancer 51
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition 51
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View 51
null 50
Paclitaxel and pazopanib in ovarian cancer 50
Recurrent mantle cell lymphoma in the uterine cervix: a case report 50
Emerging role of pemetrexed in ovarian cancer 49
Pembrolizumab in programmed death ligand 1-positive endometrial cancer 49
Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial. 49
Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma 49
null 48
Totale 6.623
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019916 0 0 0 0 0 0 0 0 0 181 398 337
2019/20202.521 338 72 67 86 238 287 320 305 294 253 165 96
2020/20211.021 112 148 99 79 52 50 24 60 99 109 122 67
2021/20222.131 25 99 179 102 286 79 53 218 181 159 318 432
2022/20232.369 488 531 115 244 263 215 51 118 195 17 90 42
2023/2024981 80 160 40 123 142 160 40 142 22 72 0 0
Totale 10.807